Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is well-positioned for long-term success, with a strong pipeline of potential treatments for serious disorders, including Cushing's syndrome, solid tumors, ALS, and MASH. The recent resubmission of the relacorilant NDA for Cushing's syndrome and positive results from the analysis requested by the FDA provide a promising outlook for approval and potential sales growth in the coming years. In addition, the completion of the pharmacy transition for their flagship drug Korlym has led to record-high patient starts, and with sales expected to improve in the next two quarters as the backlog is cleared, a return to growth is likely. The recent approval and rapid physician adoption of Lifyorli for platinum-resistant ovarian cancer also bodes well for future sales growth and continued profitability for the company. With a strong financial position and several upcoming data milestones for Lifyorli and Korlym, Corcept Therapeutics is a solid investment for long-term growth.

Corcept Therapeutics is facing significant risks related to commercial, clinical and regulatory, reimbursement, financial, legal and intellectual property, and industry factors; these risks could negatively impact its stock valuation. In its 1Q26 financial results and earnings call, the company reported lower-than-expected sales, although they are raising their revenue guidance for the year due to positive early launch signals from a new product, Lifyorli. Still, with a net loss in the first quarter and ongoing risks, analysts are maintaining a "Buy" rating on the stock but are cautious about its growth potential.